| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 43 | 2015 | 4795 | 1.600 |
Why?
|
| Neoplasms, Glandular and Epithelial | 10 | 2014 | 517 | 0.800 |
Why?
|
| Genital Neoplasms, Female | 7 | 2012 | 794 | 0.570 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2014 | 107 | 0.540 |
Why?
|
| Apoptosis | 16 | 2014 | 7757 | 0.530 |
Why?
|
| Carboplatin | 5 | 2013 | 880 | 0.490 |
Why?
|
| Receptors, Notch | 2 | 2014 | 372 | 0.460 |
Why?
|
| Polyenes | 2 | 2003 | 36 | 0.430 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 2003 | 91 | 0.410 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2003 | 162 | 0.400 |
Why?
|
| Antineoplastic Agents | 20 | 2014 | 14617 | 0.330 |
Why?
|
| Mice, Nude | 12 | 2014 | 4329 | 0.290 |
Why?
|
| Neovascularization, Pathologic | 6 | 2015 | 1586 | 0.280 |
Why?
|
| Peritoneal Neoplasms | 5 | 2014 | 859 | 0.270 |
Why?
|
| Histones | 2 | 2013 | 1513 | 0.260 |
Why?
|
| Aurora Kinases | 4 | 2012 | 193 | 0.250 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2014 | 155 | 0.250 |
Why?
|
| Cell Line, Tumor | 21 | 2014 | 14849 | 0.250 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2005 | 209 | 0.250 |
Why?
|
| Membrane Proteins | 2 | 2014 | 2928 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2015 | 1580 | 0.230 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 229 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2015 | 1269 | 0.220 |
Why?
|
| Piperazines | 1 | 2012 | 2145 | 0.220 |
Why?
|
| Drug Delivery Systems | 5 | 2008 | 661 | 0.210 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 4 | 2004 | 208 | 0.210 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2004 | 225 | 0.210 |
Why?
|
| Proteomics | 3 | 2004 | 1427 | 0.210 |
Why?
|
| Enzyme Inhibitors | 4 | 2008 | 1942 | 0.210 |
Why?
|
| Female | 63 | 2015 | 148940 | 0.200 |
Why?
|
| Organoplatinum Compounds | 5 | 2013 | 704 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2013 | 5408 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2014 | 16689 | 0.200 |
Why?
|
| Paclitaxel | 3 | 2014 | 2101 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 11 | 2005 | 5759 | 0.190 |
Why?
|
| Genes, p53 | 2 | 2009 | 1140 | 0.190 |
Why?
|
| Retinoids | 1 | 2002 | 149 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2008 | 1903 | 0.190 |
Why?
|
| Aurora Kinase B | 2 | 2012 | 67 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 2453 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2014 | 3917 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2014 | 85 | 0.170 |
Why?
|
| Uterine Neoplasms | 2 | 2014 | 576 | 0.160 |
Why?
|
| Drug Synergism | 4 | 2014 | 1356 | 0.160 |
Why?
|
| Blotting, Western | 8 | 2014 | 3584 | 0.160 |
Why?
|
| Organic Chemicals | 2 | 2013 | 103 | 0.160 |
Why?
|
| Interferon-gamma | 2 | 2006 | 1179 | 0.160 |
Why?
|
| Thiazoles | 2 | 2014 | 723 | 0.160 |
Why?
|
| Azacitidine | 4 | 2013 | 1218 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 2 | 2004 | 1109 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2014 | 9042 | 0.160 |
Why?
|
| RNA, Small Interfering | 3 | 2014 | 2196 | 0.150 |
Why?
|
| Humans | 69 | 2015 | 270740 | 0.150 |
Why?
|
| Immunohistochemistry | 9 | 2014 | 7655 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2014 | 10400 | 0.150 |
Why?
|
| Down-Regulation | 3 | 2012 | 2090 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2014 | 894 | 0.140 |
Why?
|
| Cell Proliferation | 9 | 2014 | 7238 | 0.140 |
Why?
|
| Mitotic Index | 1 | 1997 | 162 | 0.140 |
Why?
|
| Microfilament Proteins | 1 | 2000 | 494 | 0.140 |
Why?
|
| Mice | 17 | 2014 | 35600 | 0.140 |
Why?
|
| Up-Regulation | 6 | 2005 | 2422 | 0.130 |
Why?
|
| Animals | 22 | 2014 | 61956 | 0.130 |
Why?
|
| Mass Spectrometry | 3 | 2004 | 722 | 0.130 |
Why?
|
| Carrier Proteins | 2 | 2004 | 2098 | 0.130 |
Why?
|
| Aurora Kinase A | 2 | 2008 | 209 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 5149 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2006 | 3597 | 0.120 |
Why?
|
| DNA Methylation | 6 | 2013 | 2765 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 3 | 2005 | 368 | 0.120 |
Why?
|
| Kallikreins | 1 | 2014 | 86 | 0.120 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2014 | 69 | 0.120 |
Why?
|
| Receptor, Notch3 | 1 | 2014 | 39 | 0.120 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2014 | 85 | 0.120 |
Why?
|
| Dynamins | 1 | 2014 | 75 | 0.110 |
Why?
|
| Jagged-1 Protein | 1 | 2014 | 103 | 0.110 |
Why?
|
| Oleanolic Acid | 2 | 2004 | 111 | 0.110 |
Why?
|
| Leukemia, Myeloid | 3 | 2004 | 993 | 0.110 |
Why?
|
| Aneuploidy | 2 | 2005 | 382 | 0.110 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2013 | 44 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 65 | 0.110 |
Why?
|
| Tumor Burden | 3 | 2014 | 2033 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 126 | 0.110 |
Why?
|
| Endocytosis | 1 | 2014 | 232 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 2 | 2014 | 545 | 0.110 |
Why?
|
| Gene Silencing | 3 | 2011 | 827 | 0.110 |
Why?
|
| Polyunsaturated Alkamides | 2 | 2003 | 41 | 0.110 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2013 | 116 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2014 | 4961 | 0.110 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 138 | 0.110 |
Why?
|
| Acetamides | 1 | 2013 | 111 | 0.110 |
Why?
|
| Farnesyltranstransferase | 2 | 2003 | 125 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 2471 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 5 | 2014 | 4481 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 1525 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2006 | 1542 | 0.100 |
Why?
|
| DNA, Neoplasm | 3 | 2013 | 1958 | 0.100 |
Why?
|
| Cell Division | 6 | 2004 | 2657 | 0.100 |
Why?
|
| Cell Survival | 7 | 2014 | 3063 | 0.100 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2012 | 82 | 0.100 |
Why?
|
| Caspases | 2 | 2004 | 679 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 248 | 0.090 |
Why?
|
| Hyaluronic Acid | 1 | 2012 | 151 | 0.090 |
Why?
|
| Niacinamide | 1 | 2013 | 428 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1076 | 0.090 |
Why?
|
| Thrombocytosis | 1 | 2012 | 142 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 659 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2013 | 487 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2014 | 3669 | 0.090 |
Why?
|
| Adrenergic Agents | 1 | 2010 | 19 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 353 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 442 | 0.090 |
Why?
|
| Anoikis | 1 | 2010 | 63 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 266 | 0.090 |
Why?
|
| Stromal Cells | 2 | 2005 | 825 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2005 | 5593 | 0.080 |
Why?
|
| Cyclin B | 1 | 2009 | 69 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2010 | 163 | 0.080 |
Why?
|
| Signal Transduction | 7 | 2014 | 12103 | 0.080 |
Why?
|
| Biomarkers, Tumor | 5 | 2014 | 10708 | 0.080 |
Why?
|
| Patents as Topic | 1 | 2008 | 27 | 0.080 |
Why?
|
| PPAR gamma | 2 | 2012 | 225 | 0.080 |
Why?
|
| Chondroitin | 1 | 2008 | 5 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2012 | 438 | 0.080 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2012 | 499 | 0.080 |
Why?
|
| Transcriptome | 2 | 2014 | 1963 | 0.080 |
Why?
|
| Eflornithine | 2 | 1998 | 60 | 0.080 |
Why?
|
| Hypercalcemia | 1 | 2009 | 145 | 0.080 |
Why?
|
| Aspartic Acid | 1 | 2008 | 136 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2010 | 1347 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2008 | 3844 | 0.070 |
Why?
|
| S Phase | 1 | 2008 | 288 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2012 | 1050 | 0.070 |
Why?
|
| Indoles | 1 | 2013 | 1028 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 460 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 489 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 4 | 2012 | 4048 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 6256 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 497 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 1642 | 0.070 |
Why?
|
| Estrogens | 2 | 2007 | 805 | 0.070 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2007 | 169 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1336 | 0.070 |
Why?
|
| Aged, 80 and over | 9 | 2014 | 30998 | 0.070 |
Why?
|
| Pyridines | 1 | 2013 | 1313 | 0.070 |
Why?
|
| CD40 Ligand | 1 | 2006 | 130 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2009 | 1712 | 0.070 |
Why?
|
| CD40 Antigens | 1 | 2006 | 106 | 0.070 |
Why?
|
| Aged | 16 | 2014 | 73333 | 0.060 |
Why?
|
| Caspase 3 | 2 | 2004 | 474 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 1281 | 0.060 |
Why?
|
| Disease-Free Survival | 6 | 2015 | 10265 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2011 | 1716 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 2115 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2011 | 1038 | 0.060 |
Why?
|
| Fenretinide | 1 | 2005 | 100 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2004 | 322 | 0.060 |
Why?
|
| Middle Aged | 17 | 2014 | 90352 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 1838 | 0.060 |
Why?
|
| Aromatase Inhibitors | 1 | 2007 | 311 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 3409 | 0.060 |
Why?
|
| Prostaglandin D2 | 1 | 2004 | 26 | 0.060 |
Why?
|
| Cadherins | 1 | 2008 | 657 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2004 | 85 | 0.060 |
Why?
|
| Phosphorylation | 5 | 2014 | 4942 | 0.060 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2004 | 367 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2005 | 298 | 0.060 |
Why?
|
| Doxorubicin | 3 | 2007 | 3145 | 0.060 |
Why?
|
| Neoplasm Metastasis | 4 | 2005 | 5315 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 1059 | 0.060 |
Why?
|
| Quercetin | 1 | 2003 | 17 | 0.060 |
Why?
|
| Carcinoma | 2 | 2007 | 2610 | 0.060 |
Why?
|
| cdc25 Phosphatases | 2 | 2004 | 101 | 0.060 |
Why?
|
| Cell Cycle | 3 | 2013 | 2137 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 742 | 0.060 |
Why?
|
| Databases, Protein | 1 | 2003 | 101 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2004 | 299 | 0.050 |
Why?
|
| Hormone Antagonists | 1 | 2003 | 115 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2003 | 157 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 654 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 206 | 0.050 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2003 | 37 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2012 | 3035 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 1385 | 0.050 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 804 | 0.050 |
Why?
|
| Smad4 Protein | 2 | 2004 | 201 | 0.050 |
Why?
|
| Protein Multimerization | 2 | 2014 | 232 | 0.050 |
Why?
|
| Models, Biological | 3 | 2007 | 3194 | 0.050 |
Why?
|
| Adult | 13 | 2014 | 82040 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 503 | 0.050 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 3530 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2002 | 172 | 0.050 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2003 | 180 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2008 | 5438 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2002 | 230 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 841 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2003 | 1054 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2002 | 968 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2007 | 694 | 0.050 |
Why?
|
| Computational Biology | 2 | 2005 | 1291 | 0.050 |
Why?
|
| Proteome | 2 | 2002 | 571 | 0.050 |
Why?
|
| Camptothecin | 1 | 2003 | 540 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 4963 | 0.050 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 3345 | 0.040 |
Why?
|
| Mesothelioma | 2 | 2003 | 558 | 0.040 |
Why?
|
| Research | 1 | 2002 | 427 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 617 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2069 | 0.040 |
Why?
|
| DNA Primers | 3 | 2010 | 1496 | 0.040 |
Why?
|
| Dasatinib | 2 | 2014 | 881 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 1126 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 953 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2313 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2004 | 840 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 5056 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2013 | 284 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 2357 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2012 | 6390 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 5162 | 0.040 |
Why?
|
| Proteins | 2 | 2004 | 2043 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2003 | 1690 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 1584 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 2617 | 0.040 |
Why?
|
| Morpholines | 2 | 2013 | 296 | 0.040 |
Why?
|
| ErbB Receptors | 3 | 2006 | 2375 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2004 | 1624 | 0.040 |
Why?
|
| Mitochondria | 1 | 2003 | 1297 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 2345 | 0.030 |
Why?
|
| Taxoids | 2 | 2014 | 1015 | 0.030 |
Why?
|
| Leukemia | 1 | 2004 | 1719 | 0.030 |
Why?
|
| Quinazolines | 2 | 2014 | 956 | 0.030 |
Why?
|
| Receptors, LHRH | 2 | 2007 | 39 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1997 | 1189 | 0.030 |
Why?
|
| Flow Cytometry | 3 | 2006 | 3045 | 0.030 |
Why?
|
| Cisplatin | 3 | 2008 | 2497 | 0.030 |
Why?
|
| Disease Progression | 4 | 2010 | 6867 | 0.030 |
Why?
|
| Peritoneum | 2 | 2005 | 151 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 63 | 0.030 |
Why?
|
| bcl-X Protein | 2 | 2004 | 198 | 0.030 |
Why?
|
| HL-60 Cells | 2 | 2004 | 318 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2013 | 41 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 2650 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 2 | 2003 | 221 | 0.030 |
Why?
|
| Neoplasms | 2 | 2013 | 15927 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2012 | 52 | 0.030 |
Why?
|
| Microtubules | 1 | 2013 | 329 | 0.030 |
Why?
|
| Acetylation | 1 | 2013 | 515 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 168 | 0.020 |
Why?
|
| Molecular Weight | 2 | 2003 | 721 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2013 | 272 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2013 | 242 | 0.020 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 65 | 0.020 |
Why?
|
| Thrombopoietin | 1 | 2012 | 102 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2012 | 214 | 0.020 |
Why?
|
| Epigenomics | 1 | 2012 | 273 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 669 | 0.020 |
Why?
|
| Transfection | 2 | 2008 | 3117 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2015 | 967 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 5002 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 492 | 0.020 |
Why?
|
| Base Sequence | 2 | 2010 | 5437 | 0.020 |
Why?
|
| Ovarian Diseases | 1 | 2010 | 51 | 0.020 |
Why?
|
| Tretinoin | 2 | 2004 | 617 | 0.020 |
Why?
|
| Pyrazines | 1 | 2013 | 510 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 589 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 361 | 0.020 |
Why?
|
| Liposomes | 2 | 2003 | 704 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 675 | 0.020 |
Why?
|
| Cyclin G | 1 | 2009 | 10 | 0.020 |
Why?
|
| Cyclin G1 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2003 | 1437 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2009 | 60 | 0.020 |
Why?
|
| RNA | 2 | 2005 | 1063 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2010 | 162 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2012 | 9292 | 0.020 |
Why?
|
| Cytokines | 2 | 2012 | 2825 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 2 | 2004 | 885 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2010 | 283 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 617 | 0.020 |
Why?
|
| Epinephrine | 1 | 2010 | 239 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2010 | 264 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 16215 | 0.020 |
Why?
|
| Cell Line | 2 | 2008 | 5338 | 0.020 |
Why?
|
| Cyclin A | 1 | 2008 | 49 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 2311 | 0.020 |
Why?
|
| Piperidines | 1 | 2014 | 1100 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1012 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2008 | 120 | 0.020 |
Why?
|
| Benzamides | 1 | 2013 | 1879 | 0.020 |
Why?
|
| Aromatase | 1 | 2007 | 56 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 768 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 7381 | 0.020 |
Why?
|
| Cyclins | 1 | 2009 | 467 | 0.020 |
Why?
|
| Receptors, Gonadotropin | 1 | 2007 | 5 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 677 | 0.020 |
Why?
|
| Acute Disease | 2 | 2002 | 2493 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 94 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 602 | 0.020 |
Why?
|
| Gonadotropins | 1 | 2007 | 52 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 537 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 3640 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 3339 | 0.020 |
Why?
|
| Thionucleotides | 1 | 2006 | 66 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 1340 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 336 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 4147 | 0.020 |
Why?
|
| Cytarabine | 2 | 2002 | 2014 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 255 | 0.020 |
Why?
|
| Mitosis | 1 | 2007 | 681 | 0.020 |
Why?
|
| Agar | 1 | 2004 | 26 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6224 | 0.020 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2004 | 94 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 442 | 0.010 |
Why?
|
| U937 Cells | 1 | 2004 | 178 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2004 | 24 | 0.010 |
Why?
|
| Dimerization | 1 | 2004 | 311 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2004 | 319 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2013 | 1933 | 0.010 |
Why?
|
| Progesterone | 1 | 2007 | 711 | 0.010 |
Why?
|
| Chromones | 1 | 2004 | 121 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 44 | 0.010 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2003 | 7 | 0.010 |
Why?
|
| Androgens | 1 | 2007 | 506 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 164 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 147 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2004 | 374 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2003 | 7265 | 0.010 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2004 | 162 | 0.010 |
Why?
|
| Technetium | 1 | 2003 | 79 | 0.010 |
Why?
|
| Retrospective Studies | 4 | 2009 | 39890 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 208 | 0.010 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2003 | 123 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2006 | 743 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2004 | 292 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 938 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 2454 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 5101 | 0.010 |
Why?
|
| Bridged-Ring Compounds | 1 | 2003 | 190 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2014 | 33737 | 0.010 |
Why?
|
| Topotecan | 1 | 2003 | 248 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 80 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2003 | 222 | 0.010 |
Why?
|
| Thalidomide | 1 | 2006 | 597 | 0.010 |
Why?
|
| Ascites | 1 | 2003 | 213 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 936 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 373 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 293 | 0.010 |
Why?
|
| Annexin A2 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2004 | 572 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 655 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 5728 | 0.010 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2003 | 180 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 524 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 1012 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2002 | 189 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2002 | 118 | 0.010 |
Why?
|
| Annexin A1 | 1 | 2002 | 41 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 927 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 729 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2002 | 88 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 143 | 0.010 |
Why?
|
| fas Receptor | 1 | 2002 | 197 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 337 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 4831 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 3028 | 0.010 |
Why?
|
| Ovary | 1 | 2005 | 688 | 0.010 |
Why?
|
| CpG Islands | 1 | 2003 | 671 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 1810 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2004 | 672 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 848 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2002 | 640 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 1111 | 0.010 |
Why?
|
| Blast Crisis | 1 | 2003 | 588 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 2472 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 575 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 467 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 2170 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 805 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 1028 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 702 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2012 | 2887 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 5824 | 0.010 |
Why?
|
| Imidazoles | 1 | 2004 | 1065 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 4000 | 0.010 |
Why?
|
| Image Cytometry | 1 | 1997 | 44 | 0.010 |
Why?
|
| Testosterone | 1 | 2003 | 638 | 0.010 |
Why?
|
| Neutropenia | 1 | 2001 | 1006 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2003 | 1710 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 2600 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 1998 | 247 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2001 | 870 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 2651 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 3216 | 0.010 |
Why?
|
| Anemia | 1 | 2001 | 728 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 1367 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2003 | 14012 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 4567 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1997 | 984 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 6177 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1997 | 622 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 6685 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 4116 | 0.010 |
Why?
|
| Male | 3 | 2013 | 128315 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 22505 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 17888 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 13006 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 3707 | 0.000 |
Why?
|
| Biomarkers | 1 | 1998 | 5051 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 7914 | 0.000 |
Why?
|